eligibility_summary
During cell procurement and lymphodepletion, standard-of-care chemo/radiation may be used to stabilize disease, eligibility must be maintained to proceed to each phase. Inclusion: informed consent/HIPAA, age ≥18, Karnofsky >60%, classical Hodgkin lymphoma (WHO). Exclusion: major surgery within 28 days, investigational agents/tumor vaccines within 3 weeks, chemotherapy or radiation within 3 weeks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: ATLCAR.CD30.CCR4—autologous, gene‑modified T cells (CAR T). Mechanism: CAR recognition of CD30 on Hodgkin/Reed–Sternberg cells triggers T‑cell activation and cytotoxicity, co-expression of CCR4 is intended to enhance trafficking to the HL microenvironment rich in CCR4 ligands (CCL17/CCL22). Lymphodepletion before infusion: bendamustine (alkylating agent) 70 mg/m2 IV and fludarabine (purine analog/antimetabolite) 30 mg/m2 IV daily ×3 to deplete host lymphocytes and support CAR T expansion. Targets: CD30 (TNFR family) on malignant cells, CCR4/CCL17–CCL22 chemokine axis for homing, resultant T-cell effector pathways for tumor lysis. Population: relapsed/refractory CD30+ classical HL.